Compare CHH & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHH | ITGR |
|---|---|---|
| Founded | 1939 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.3B |
| IPO Year | 1997 | 2000 |
| Metric | CHH | ITGR |
|---|---|---|
| Price | $98.39 | $126.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $114.30 | $91.14 |
| AVG Volume (30 Days) | 441.6K | ★ 663.7K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 1.84 | 1.17 |
| Revenue | $1,596,793,000.00 | ★ $1,853,637,000.00 |
| Revenue This Year | $66.74 | $1.69 |
| Revenue Next Year | $0.37 | $6.53 |
| P/E Ratio | ★ $53.39 | $108.01 |
| Revenue Growth | 0.75 | ★ 7.98 |
| 52 Week Low | $84.04 | $62.00 |
| 52 Week High | $123.82 | $126.80 |
| Indicator | CHH | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 34.92 | 76.74 |
| Support Level | $93.51 | $124.84 |
| Resistance Level | $98.71 | $126.80 |
| Average True Range (ATR) | 3.14 | 0.29 |
| MACD | -0.64 | -0.81 |
| Stochastic Oscillator | 10.83 | 65.07 |
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.